332 related articles for article (PubMed ID: 22720323)
1. Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease.
Alexander PM; Eastaugh L; Royle J; Daley AJ; Shekerdemian LS; Penny DJ
J Paediatr Child Health; 2012 May; 48(5):395-401. PubMed ID: 22720323
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study.
Butt M; Symington A; Janes M; Steele S; Elliott L; Chant-Gambacort C; Mondal T; Paes B
Cardiol Young; 2014 Apr; 24(2):337-43. PubMed ID: 23628233
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
Ratti C; Greca AD; Bertoncelli D; Rubini M; Tchana B
Ital J Pediatr; 2023 Jan; 49(1):4. PubMed ID: 36631870
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
[TBL] [Abstract][Full Text] [Related]
6. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
[TBL] [Abstract][Full Text] [Related]
7. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
Prais D; Schonfeld T; Amir J;
Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
9. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.
Banerji A; Panzov V; Young M; Lee BE; Mamdani M; Giles BL; Dennis M; Morel J; Bisson D; Paes BA; Hui C; Mahony J
Can Respir J; 2014; 21(3):185-9. PubMed ID: 24367792
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
11. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
Forbes ML; Kumar VR; Yogev R; Wu X; Robbie GJ; Ambrose CS
Hum Vaccin Immunother; 2014; 10(10):2789-94. PubMed ID: 25483663
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.
Winterstein AG; Eworuke E; Xu D; Schuler P
Pediatr Pulmonol; 2013 Sep; 48(9):874-84. PubMed ID: 23139089
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus.
Ohler KH; Pham JT
Am J Health Syst Pharm; 2013 Aug; 70(15):1342-6. PubMed ID: 23867491
[TBL] [Abstract][Full Text] [Related]
16. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
17. [Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society].
Chantepie A;
Arch Pediatr; 2004 Nov; 11(11):1402-5. PubMed ID: 15519844
[TBL] [Abstract][Full Text] [Related]
18. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations.
Rackham OJ; Thorburn K; Kerr SJ
Cardiol Young; 2005 Jun; 15(3):251-5. PubMed ID: 15865826
[TBL] [Abstract][Full Text] [Related]
19. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
Feltes TF; Sondheimer HM
Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
